Agios 制药 AGIO
$29.41 +$1.14 (+4.03%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $28.97 -1.50%
开盘$28.99
昨收$28.27
当日区间$28.46 – $29.80
成交量1.28M
市值$1.76B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例115.2%+3.04 个百分点，较上季度
持仓机构数289+4 ，较上季度
内部人近期交易37次买入 / 13次卖出净买入
空头持仓比例11.55% 占流通股回补天数 5.6 · 截至 15 Oct 2026
卖空成交量占比21.5%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：+$6.55M（8个净流入日，12个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有37.6%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从11.46%升至11.55%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +1,782,457 | 3.2% |
| ADAR1 Capital Management, LLC | Hedge Fund | 2026/Q3 | +1,147,381 | 2.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +859,521 | 1.8% |
| Lynx1 Capital Management LP | Mutual Fund | 2026/Q3 | +797,369 | 5.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +701,040 | 10.8% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +640,748 | 1.1% |
| Macquarie Investment Management Business Trust | Mutual Fund | 2026/Q3 | +616,374 | 3.5% |
| Arrowstreet Capital, Limited Partnership | Mutual Fund | 2026/Q3 | +560,069 | 1.4% |
| Defilade Capital Management, L.P. | Hedge Fund | 2026/Q3 | +546,848 | 0.9% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +506,344 | 0.8% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +425,836 | 5.2% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +409,971 | 1.0% |
| Schonfeld Strategic Advisors LLC | Hedge Fund | 2026/Q3 | +320,022 | 0.9% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +314,734 | 1.7% |
| Ensign Peak Advisors Inc. | Mutual Fund | 2026/Q3 | +291,060 | 0.5% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 25 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -7,866 | $37.69 | – |
| 21 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -500 | $37.52 | – |
| 21 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -1,989 | $37.53 | 54,645 |
| 20 Oct 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Intent to Sell (Form 144) | -1,489 | $37.53 | – |
| 3 Aug 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -30,000 | $30.48 | 54,645 |
| 7 Jul 2026 | Jay Backstrom | Independent Director | Other Acquisition | +1,447 | – | 1,447 |
| 30 Jun 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -4,007 | $37.56 | 84,645 |
| 30 Jun 2026 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Retained | +4,368 | – | 84,645 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Jacqualyn Fouse | Chair of the Board of Directors | Derivative Exercise and Retained | +2,816 | – | 154,156 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Jeffrey Capello | Independent Director | Derivative Exercise and Retained | +2,816 | – | 10,865 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Kaye Foster-Cheek | Lead Independent Director | Derivative Exercise and Retained | +2,816 | – | 12,484 |
| 17 Jun 2026 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
| 17 Jun 2026 | Jay Backstrom | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 | 14,950 |
| 17 Jun 2026 | Maykin Ho | Independent Director | Other Derivative Acquisition | +2,927 | – | 2,927 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 6,894,856 | 11.5% | 5.6 |
| 30 Sep 2026 | 7,016,166 | 11.8% | 6.4 |
| 15 Sep 2026 | 7,557,252 | 12.7% | 9.5 |
| 31 Aug 2026 | 7,535,054 | 12.6% | 8.4 |
| 14 Aug 2026 | 7,629,012 | 12.8% | 7.0 |
| 31 Jul 2026 | 6,840,722 | 11.5% | 5.1 |
暂无评论——快来第一个聊聊 AGIO。
登录后参与讨论。